SYS-CON MEDIA Authors: Wayne Ariola

News Feed Item

Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes

NEW BRUNSWICK, N.J., Sept. 26, 2012 /PRNewswire-FirstCall/ -- Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Tuesday, October 2, at approximately 12:00 p.m., Eastern Time, to coincide with the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany.

First results from the ongoing phase 3 CANVAS trial evaluating canagliflozin in patients with type 2 diabetes at elevated risk for cardiovascular disease will be shown at EASD.  Additionally, data from DIA3010, which evaluated canagliflozin as add-on therapy in patients aged 55 to 80, on antihyperglycemic therapy without adequate glycemic control, will be presented.

A pre-recorded webcast with Kirk Ways, M.D., Ph.D, Vice President and compound development team leader for canagliflozin from Janssen Research & Development, will provide an update on the CANVAS sub-study and DIA3010 results.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."

SOURCE Johnson & Johnson

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.